Sunday, November 23, 2008

ASU Biomedical Informatics professor elected to the Fellowship of the American College of Medical Informatics (ACMI).

ASU Biomedical informatics professor honored by national group

Doug Fridsma, an associate professor in the Department of Biomedical Informatics, has been elected to the Fellowship of the American College of Medical Informatics (ACMI).

Fridsma’s research involves the development of tools to study patient safety, clinical work processes, and collaboration between healthcare providers, with a focus on simulation, clinical trials and oncology care.

Selection to ACMI Fellowship is an honor reserved for individuals with typically more than a decade of significant and sustained contributions to medical informatics.

Fridsma is one of the primary developers of the Biomedical Research Integrated Domain Group Project, a division of the Biomedical Informatics Grid Program, the Clinical Data Interchange Standards Consortium and Health Level 7 that is working to develop a comprehensive and formal representation of the shared semantics of clinical trials research.

Fridsma previously was an assistant professor at the University of Pittsburgh’s biomedical informatics department.



Arizona Internet Marketing

Arizona Biotechnology Marketing
Biotechnology News

Friday, November 14, 2008

TGEN NEWS - Dr. Von Hoff is named Arizona's 'Community Service Leader of the Year' at Governor’s Celebration of Innovation

TGen's Dr. Von Hoff is named Arizona's 'Community Service Leader of the Year' at Governor’s Celebration of Innovation

Arizona Internet Marketing

PHOENIX, Ariz. - Nov. 13, 2008 -- Dr. Daniel Von Hoff, a world-renowned cancer scientist and Physician-In-Chief of the Translational Genomics Research Institute (TGen), was named Arizona's Community Service Leader of the Year today at the 2008 Governor’s Celebration of Innovation.

Dr. Von Hoff, who also is Chief Scientific Officer of TGen Clinical Research Services at Scottsdale Healthcare, won the William F. McWhortor Community Service Leader of the Year award, presented annually to an individual or organization from industry, government or academia that contributes to Arizona's technology industry through relentless community involvement, leadership, visibility and excellence in economic development activity.

"Dr. Von Hoff has devoted a lifetime toward advancing the understanding and treatment of cancer. He shared the vision for the establishment of (TGen) a premier center for the application of the understanding of the human genome to the treatment of diseases," according to the presentation made by the Arizona Technology Council in partnership with the Arizona Department of Commerce and the Honorable Janet Napolitano, Governor of Arizona.

"The quality and diversity of this year's award recipients is a positive indication that technological innovation in both large established and emerging small companies is thriving in Arizona," said Steven G. Zylstra, president and CEO of the Arizona Technology Council.

The prestigious awards ceremony, celebrating excellence in innovative technological advancement, was emceed at the Dodge Theatre by author Jane Poynter, one of eight people who lived sealed for two years in the early 1990s inside the artificial environment near Tucson known as Biosphere 2. She now is President of Paragon Space Development Corp., which develops technologies for extreme environments, such as space, under water and hyper-efficient buildings.

Other winners included:

-- Paolo Soleri – Lifetime Achievement Award in recognition of his many contributions in addressing environmental sustainability. Soleri is an internationally recognized Paradise Valley architect, artist and philosopher, and creator of the innovative city Arcosanti.

-- Jeff Morhet – Ed Denison Business Leader of the Year Award. Morhet is President and Chief Executive Officer of InNexus Biotechnology Inc., a drug development company at the Mayo Clinic Collaborative Research Building in Scottsdale.

-- Rep. Michele Reagan, R-Scottsdale, "Representative of the Year."

-- Sen. Barbara Leff, R-Paradise Valley, "Senator of the Year."

*

In addition to his work at TGen, Dr. Von Hoff is Clinical Professor of Medicine at the University of Arizona, and a member of the Mayo Clinic's Comprehensive Cancer Center.

Dr. Von Hoff is a founder of TGen, a founder of the non-profit International Genomics Consortium based in Phoenix, and has helped bring countless other jobs to this community. His commitment was instrumental in helping establish the Scottsdale Clinical Research Institute, a hospital-based research institute that serves as a bridge between cure and care. It is one of the finest programs in the nation in its ability to help patients with advanced cancer. It is emblematic of the translation of discoveries in genomic science to specific treatments for individual patients.

Dr. Von Hoff earned his medical degree at Columbia College of Physicians and Surgeons in 1973. Following an internship and residency at the University of California, San Francisco, he spent four years at the prestigious National Cancer Institute in Bethesda, Md.

After experience at the forefront of cancer research at NCI, he joined the faculty of the University of Texas in San Antonio, where during the next 20 years he expanded the knowledge of cancer biology and tumor growth factors.

Dr. Von Hoff moved to Arizona in 1999, serving as Director of the Arizona Cancer Center in Tucson, and as Professor at the University of Arizona College of Medicine in Tucson, before joining TGen.

In addition to his other duties, Dr. Von Hoff is serving a six-year presidential appointment (June 2004-March 2010) on the National Institutes of Health’s National Cancer Advisory Board. He also is past president of the American Association for Cancer Research, which with more than 28,000 members is the world's largest cancer research organization. He has published more than 540 scientific papers, more than 130 book chapters, and nearly 950 scientific abstracts. He is the holder of a dozen patents for new anti-cancer agents and medical devices.

For more than 35 years, Dr. Von Hoff has been devoted to advancing the understanding and treatment of cancer. His programs have two main goals:

-- Applying new knowledge to identify the best new targeted anti-cancer agents to treat individual cancer patients.

-- Curing pancreatic cancer.

The William F. McWhortor Community Service Leader of the Year award is named in honor of the late co-founder of the Arizona Innovation Network and its successor professional groups in Arizona, including the Arizona Technology Council, which have supported creative technological thinking. McWhortor, a Fountain Hills resident who died in 1997, patented a pattern recognition device in 1989 to help stop counterfeit checks.

Past winners of the McWhortor award include:

-- Ira A. Fulton, chairman and chief executive officer of Tempe-based Fulton Homes Inc.

-- Former Arizona State University President Lattie Coor.

-- Richard Mallery, partner and founding director of the Phoenix law firm Snell & Wilmer, for his successful efforts to bring the Translational Genomics Research Institute to Arizona.

*

About the Governor's Celebration of Innovation
The Governor's Celebration of Innovation was established in 2003 by combining two technology award ceremonies: the High Tech Industry Cluster’s 17-year Innovator of the Year awards ceremony and the Arizona Software and Internet Association's 10-year "Celebration of Innovation." With the addition of the Governor’s support, the Governor’s Celebration of Innovation has become the premier technology community gathering of its kind in Arizona. For more information on GCOI, please visit http://www.aztechcouncil.org.

About the Arizona Technology Council
The Arizona Technology Council is a private, not-for-profit trade association founded to connect, represent and support the state's expanding technology industry. To promote economic growth and professional development in Arizona's technology sector, the Council provides members networking opportunities, business support and access to educational forums. The Council strives to distinguish Arizona as a leader in the technology community and offer resources that are exclusive to its members. To become a member or to learn more about the Arizona Technology Council, please visit http://www.aztechcouncil.org.

About the Arizona Department of Commerce
Collaborating with economic development partners statewide, the Arizona Department of Commerce works to create jobs, expand the tax base, increase per capita income and promote a globally competitive business environment. The agency provides reliable information and research, community assistance, targeted business attraction and development coupled with strategic workforce development. Nationally and internationally, the Department of Commerce promotes Arizona assets: a growing, high-tech workforce; competitive operating environment; easy access to major markets; affordable, available real estate; reliable utilities; abundant natural resources and an unmatched quality of life. For more information, visit www.azcommerce.com.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process. www.tgen.org.


Biotechnology Marketing
Biotechnology News

Labels: , ,

First Alana’s Champs 5K to fund TGen brain cancer efforts

First Alana’s Champs 5K run to fund TGen brain cancer efforts

Fundraising race held in memory of TGen neurogenomics researcher

First Alana’s Champs 5K to fund TGen brain cancer efforts


PHOENIX, Ariz. - Nov. 14, 2008 –– The first Alana’s Champs 5K, a run and walk to benefit brain cancer research at the Translational Genomics Research Institute (TGen), is set for Dec. 6 at Wesley Bolin Memorial Plaza.

The event is named for Alana Lysholm-Bernacchi, a TGen neurogenomics researcher who studied hearing loss, Down syndrome and amyotrophic lateral sclerosis (ALS), often referred to as Lou Gehrig’s Disease. She died as the result of a brain tumor on Dec. 3, 2007.

Alana’s Champs 5K is coordinated by the TGen Foundation, Arizona Road Racers and by Brett Bernacchi, a TGen volunteer and the husband of Alana.

If you go

Where: Wesley Bolin Memorial Plaza, just east of the Arizona State Capitol, 1700 W. Washington St., Phoenix.

When: Dec. 6. Event-day registration starts at 7 a.m.; the 5-kilometer run starts at 8 a.m.; the 5K walk at 8:10 a.m.; and the 1-mile run/walk at 8:45 a.m., followed by a kids dash and raffle.

Participation Fees:
– Ages 13 and up: $20 if pre-registered by Nov. 16; $25 from Nov. 16-Dec. 5; and $30 on Dec. 6.
– Ages 5-12: $5 if pre-registered by Nov. 16; $10 from Nov. 15-Dec. 6.
– Children ages 4 and younger are free.

Details: Please visit the TGen Foundation at www.helptgen.org or call Erin Massey, assistant director of development, at 602-343-8470.

About TGen
The Translational Genomics Research Institute (TGen) is a non-profit organization dedicated to conducting groundbreaking research with life changing results. Research at TGen is focused on helping patients with diseases such as cancer, neurological disorders and diabetes. TGen is on the cutting edge of translational research where investigators are able to unravel the genetic components of common and complex diseases. Working with collaborators in the scientific and medical communities, TGen believes it can make a substantial contribution to the efficiency and effectiveness of the translational process.

Bill Austin

Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

Labels: ,

Wednesday, November 12, 2008

RECOMB 2009 - computational biology and applications in molecular biology and medicine

May 18 - 21, 2009 - RECOMB 2009
Widely considered to be the most prestigious conference in computational biology, RECOMB invites paper presentations and poster submissions from the international community of computer scientists, mathematicians, statisticians, and computational biologists. RECOMB provides a scientific forum for theoretical advances in computational biology and applications in molecular biology and medicine. For more information, click here.



Biotechnology News
Arizona Biotechnology Marketing
Arizona Internet Marketing


Tuesday, November 11, 2008

Arizona Biotechnology SBIR/STTR Seminar

December 12 - SBIR/STTR Seminar
Come learn about the Small Business Innovation Research Programs (SBIR), the federal government's largest R&D outreach program targeted to the small business community with approximately $2 billion in funds available annually. This program is one of the best sources of available capital to fund the development of new technologies. For more details, click here or visit www.azbio.org



Arizona Internet Marketing
Biotechnology News

Monday, November 10, 2008

AZBio/BIO-SA Breakfast (Tucson)

Arizona Internet Marketing

November 21 - AZBio/BIO-SA Breakfast (Tucson)
Register here to attend the next monthly AZBio/BIO-SA Breakfast. Held at Acacia (St. Philips Plaza), this presentation is entitled "sanofi-aventis: Escaping the Privileged Classes". Ken Wertman, Scientific Director of sanofi-aventis' site in Oro Valley will cover working outside known chemical families (so called privileged classes), and provide an overview of the company's strategy, and what the company's purpose and plans are for the Tucson group.



Arizona Biotechnology Marketing
Biotechnology News

Sunday, November 09, 2008

InNexus Biotechnology Inc., OTC Bulletin Board: IXSBF TSX Venture: IXS

Arizona Biotechnology Marketing
Biotechnology News

InNexus Biotechnology Announces New EGFR Antibody DXL1218 Targeting Colorectal Cancer and Announces $1.25 Million Private Placement



- Innovative Biotech Targets Another Large Well-Known Product and Continues
Expansion of Antibody Therapeutics Pipeline -

InNexus Biotechnology Inc., (OTC Bulletin Board: IXSBF; TSX Venture: IXS;
http://www.ixsbio.com), a drug development company commercializing the next
generation of monoclonal antibodies based on its Dynamic Cross Linking
(DXL(TM)) technology, announces the development of a new antibody product
from its DXL(TM) platform technology, DXL1218 (EGFR), for the prospective
treatment of colorectal cancer.

"Recent experimental data suggests that DXL1218 (EGFR) is superior to
competing commercialized products on the market, such as ERBITUX(R)
(cetuximab), in terms of potency and efficacy," said Jeff Morhet, CEO and
Chairman of InNexus. "I am very excited, as this latest development lends
further support to the robustness and predictability of the DXL(TM)
platform and the superiority of products from the platform over presently
commercialized offerings."

Speaking on InNexus' announcement, Pablo Legorreta, Chief Executive
Officer of Royalty Pharma said, "We are quite pleased with the rapid
progress of our research partner InNexus. Jeff has had a vision for rapid
product development based on DXL(TM) technology coupled with advanced in
vivo studies and a significant regulatory strategy. We look forward to
their continued rollout of products and performance."

Private Placement

InNexus also announces it intends to issue 10% unsecured convertible
debentures, for maximum proceeds to InNexus of $1.25 million. Each
debenture will be convertible into common shares of InNexus at the rate of
one common share for each $0.10 of debt converted. The debenture will have
a term of 2 years and net proceeds from the private placement will be used
by InNexus for research and development and general corporate business.
Closing of the private placement is expected to occur on or about 14
November 2008.

In connection with the private placement, certain insiders of InNexus
comprised of some members of the Board and senior management, are expected
to participate in the offering for an aggregate of approximately 40% on the
same terms and InNexus may pay finders' fees to registered persons in an
amount equal to 7% of the proceeds from the sale of the debentures to
purchasers referred by such finder in accordance with the policies of the
TSX Venture Exchange.

Participation in the private placement by insiders of InNexus is
considered to be a related-party transaction as defined under Multilateral
Instrument 61-101, however, the transaction is exempt from the formal
valuation and minority shareholder approval requirements under the
instrument as neither the fair market value of the securities being issued
nor the consideration paid exceeds 25 per cent of InNexus' market
capitalization.

Upon conversion of the debenture, the common shares will be subject to
a four-month "hold period" from the date of conversion under the policies
of the TSX Venture Exchange and applicable securities legislation.

About Colorectal Cancer

Colorectal cancer is the third most common cancer found in men and
women in the United States and is a term referring to cancer that develops
in the colon or rectum. The American Cancer Society estimates that there
will be about 108,070 new cases of colon cancer and 40,740 new cases of
rectal cancer in 2008 in the United States. Combined, they will cause about
49,960 deaths.

One of the leading products available is ERBITUX(R) (cetuximab)
marketed by ImClone Systems Incorporated. ImClone recently reported that
global net sales of ERBITUX(R) for the first quarter of 2008 grew to $417.3
million, an increase of 12% compared to $371.0 million for the previous
quarter and an increase of 36% compared to $306.1 million for the same
period last year.

About InNexus

InNexus is a drug development company commercializing the next
generation of monoclonal antibodies based on its DXL(TM) technology, which
improves the potency of existing antibody products while opening new
markets and disease applications. DXL(TM) antibodies utilize unique, novel
and patented methods and technologies of InNexus.

InNexus is headquartered in British Columbia with principal management
based in Scottsdale, Arizona on the campus of Mayo Clinic and has its own
in-house developmental facilities. These development resources provide
validation of protein and peptide discoveries, enabling InNexus (and its
strategic partners) to advance novel drug therapeutics and diagnostics. To
learn more about InNexus, please visit http://www.ixsbio.com.

The TSX Venture Exchange has not reviewed and does not accept
responsibility for the adequacy or accuracy of this news release. This news
release may contain assumptions, estimates, and other forward-looking
statements that involve inherent risks and uncertainties and are subject to
factors, many of which are beyond the Company's control, that may cause
actual results or performance to differ materially from those currently
anticipated in such statements.



SOURCE InNexus Biotechnology Inc.

Arizona Internet Marketing

Biotechnology Industry Organization (BIO) Congratulates President-Elect Obama

BIO Congratulates President-Elect Obama on His Presidential Election Victory


The following statement was issued today by Biotechnology Industry Organization (BIO) President and CEO Jim Greenwood following U.S. elections:

"On behalf of the more than 1,200 members of the Biotechnology Industry Organization, I offer our congratulations to Senator Barack Obama on
his election victory. We also offer our congratulations to the newly elected and returning members of Congress, governors and other elected officials across the United States.

"From health care to energy to climate change to environmental sustainability, President-elect Obama will enter office facing a daunting array of complex challenges threatening the well-being of our nation and the environmental health of our planet.

"Biotechnology is uniquely suited to help provide answers to these challenges. Biotechnology provides hope for millions of people suffering from debilitating diseases like cancer, H.I.V.-AIDS, Parkinson's and diabetes. By reducing the incidence of disease, we can dramatically reduce health care costs and help spur economic growth. Biotechnology provides the key to sustainable, renewable alternative fuels that increase our nation's energy security. And we develop crops that produce more food per acre while requiring less plowing, reducing fuel use, carbon dioxide emissions, and overall environmental impact.

"Biotechnology is one of the most promising sectors of America's burgeoning innovation economy. To continue our nation's global leadership in innovation and continue to fulfill the promise of biotechnology, we will work with President-elect Obama and the new Congress to ensure that we have the proper public policies that promote and facilitate continued innovation.

"We must maintain strong protections for intellectual property - the key to an innovation economy - while enhancing patent quality and the objectivity, predictability, and transparency of the patent system. We must increase resources for the Federal Food and Drug Administration to enable the agency to keep pace with rapidly evolving biomedical science and make sound regulatory decisions in a timely and efficient manner. We must provide the tax and investment incentives that promote continued biotech innovation and help accelerate the commercialization of advanced biofuels technologies. And we must ensure the National Institutes of Health have the funding needed to sustain the public-private collaboration that is transforming biomedical discoveries into innovative treatments for patients. At the same time, we need the proper policies and incentives at the state and local level to help grow and nurture biotechnology research and product development to ensure America remains the world leader in biotechnology innovation.

"We look forward to working with President-elect Obama, the new Congress and public officials at all levels of government to achieve these goals and continue to build our nation's innovation economy. Together, we can implement the public policies necessary to help heal, fuel, feed and clean our nation."

About BIO

BIO represents more than 1,200 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world's largest gathering of the biotechnology industry, along with industry-leading investor and partnering meetings held around the world.

Upcoming BIO Events -0- Advanced Business Development Course November 14-16, 2008 Mannheim/Heidelberg, Germany BIO-Europe 2008 November 17-19, 2008 Mannheim/Heidelberg, Germany BIO-Asia Partnering Conference 2009 January 19-20, 2009 Tokyo, Japan BIO CEO & Investor Conference 2009 February 9-11, 2009 New York, New York BIO-Europe Spring March 16-18, 2009 Milan, Italy BIO Windhover 2009 April 13-15, 2009 New York, New York 2009 BIO International Convention May 18-21, 2009 Atlanta, Ga. BioEquity Europe June 9-10, 2009 Munich, Germany World Congress on Industrial Biotechnology & Bioprocessing July 19-22, 2009 Montreal, Quebec, Canada

Offers Commitment to Work Cooperatively To Grow the Innovation
Economy To Heal, Fuel, Clean and Feed the U.S. and the World

Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotechnology News

ACGME Competencies: Evaluation, Scholarly Activities, and Quality Improvement

November 20 - ACGME Competencies: Evaluation, Scholarly Activities, and Quality Improvement
Join the academic faculty and advisor from around the Valley for training on how to link the six general competencies of the Accreditation Council for Graduate Medical Education (ACGME), scholarly activities, and quality improvement. Don't miss this learning opportunity to network and learn from people who have a passion for excellence in graduate medical education. For more information, click here.



Arizona Internet Marketing
Arizona Biotechnology Marketing
Biotech News

Friday, November 07, 2008

Special Event: G. Steven Burrill: Biotech 2008 -- Life Sciences: A 20/20 Vision for 2020 (Tucson & Phoenix)

November 12 - Special Event: G. Steven Burrill: Biotech 2008 -- Life Sciences: A 20/20 Vision for 2020 (Tucson & Phoenix)
Don't miss this special event! G. Steven Burrill is a world-renowned biotech visionary, will be in Tucson and Phoenix next week. According to the 22nd annual report on the biotechnology industry from Burrill & Company, the convergence of genomics, information technology, and nanotechnologies will radically alter every aspect of the healthcare system from the way companies develop and market drugs and devices to the way individuals pay for and receive medical services. Mr. Burrill's presentation also highlights the developments in 2007 across all sectors including human healthcare, biofuels, agbio, and industrial biotechnology.
AZBio has teamed with The Stratford Group to bring Mr. Burrill to Arizona for a breakfast talk in Tucson, followed by a lunch presentation in Phoenix. Space is limited for this exciting presentation by one of the leading Life Sciences investment bankers and venture capitalists. For more information and to register, click here or visit www.azbio.org. Space is limited.



Biotechnology Marketing

Thursday, November 06, 2008

AZ Biotech - Peer2Peer Luncheon: The FDA's Growing Emphasis on Human Factors (Tempe)

Biotechnology Marketing


Internet Marketing

November 13: Peer2Peer Luncheon: The FDA's Growing Emphasis on Human Factors (Tempe)
Next year the FDA is expected to adopt its newest and most comprehensive human factors standard: HE 75 - Human Factors Design for Medical Devices. While FDA human factors standards and guidelines have been around for over 15 years, the lack of resources and expertise caused little attention to be paid to the issue. Plan to attend, meet with senior representatives of bioscience companies and discuss this issue. To sign up,
click here or visit www.azbio.org

Biotech News

Monday, November 03, 2008

AZBio/BIOSA Mixer (Tucson)

November 6 - AZBio/BIOSA Mixer (Tucson)
Don't forget to sign up - this Thursday, we're meeting at the El Parador to relax, network, mingle, and maybe talk about election results. The mixer starts at 5:30pm.
Sign up here.


Biotech News